Pierre Fabre ambispective non-small cell lung cancer OCTOPUS study

• Research type

  Research Study

• Full title

  An ambispective observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.

• IRAS ID

  310116

• Contact name

  Jason Adhikaree

• Contact email

  jason.adhikaree@nuh.nhs.uk

• Sponsor organisation

  Pierre Fabre SA (PFSA)

• Duration of Study in the UK

  2 years, 10 months, 1 days

• Research summary

  This is a non-interventional study with the goal to describe treatment patterns for metastatic Non-Small Cell Lung Cancer(mNSCLC).

  Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnoses. Approximately 40% of newly diagnosed NSCLC patients have stage IV disease. The 5-year survival rate for patients diagnosed with NSCLC is 24%. Approximately 1% to 8% of patients with NSCLC harbour a BRAF-mutation. The most common BRAF mutation, the V600E, is observed in 1-2% of lung adenocarcinomas.

  This study will describe the treatment patterns in clinical practice in adult patients with mNSCLC with a BRAF V600E mutation (specific gene mutation) and assess Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) as well as safety of each treatment

• REC name

  London - Central Research Ethics Committee

• REC reference

  22/PR/0725

• Date of REC Opinion

  29 Jul 2022

• REC opinion

  Favourable Opinion